



HPLC METHOD DEVELOPMENT : A REVIEW

Kurkute D. G ,² DR. Lokhande R .P.

¹Student , ²Asst Proffessor .

¹ Department of pharmaceutical chemistry ,
¹Samarth Institute of Pharmacy, Belhe, Junnar,Pune.

Abstract : They serve as a foundation for choices on how best to give medications to patients, and they are crucial to the discovery, development, and production of pharmaceuticals as well as a host of other human and animal health-related research projects. Validation of analytical methods is necessary for both medication research and manufacturing, and these methods are suitable for the intended use. Pharmaceutical companies need to establish an overall validation policy that outlines the process for performing validation in order to comply with GMP regulations. The optimization of HPLC settings is the primary topic of this essay. A sequence of events required for method development and analytical validation are described.

IndexTerms - HPLC , Analytical method validation, Pharmaceutical analysis, Specificity,Precision,Accuracy.

INTRODUCTION

INTRODUCTION PARTITION CHROMATOGRAPHY

Partition chromatography can be subdivided into

- (i) liquid-liquid chromatography
- (ii) bonded-phase chromatography.

In bonded-phase, the stationary phase is chemically attached to the support surfaces; in liquid-liquid, a liquid stationary phase is held on the packing surface by physical adsorption. Due to some drawbacks with liquid-liquid systems, the bonded-phase approach has supplanted the liquid-liquid type in partition chromatography.

One of these drawbacks is that the support particles must be periodically recoated due to the loss of stationary phase due to dissolution in the mobile phase. Moreover, gradient elution cannot be performed using liquid-phase packings due to stationary-phase solubility issues.

Journal of Pharmaceutical

Columns for Bonded-Phase Chromatography.

For partition chromatography, stiff silica, or silica-based, compositions are used to prepare the supports for most bonded-phase packings. These solids are typically composed of homogeneous, porous, mechanically robust particles with sizes of 3, 5, or 10 µm. Fully hydrolyzed silica has silanol groups on its surface that are reactive to chemicals. The most practical bonded-phase coatings are siloxanes, which are created when an organochlorosilane reacts with the hydrolyzed surface.





Figure-1 HPLC PARTS

HPLC classified by
LBASED ON MODE OF SEPERATION

1. Normal phase chromatography, where the mobile phase is non-polar (hydrophobic) and the stationary phase is polar (hydrophilic).
2. Reverse phase chromatography, where the mobile phase is polar (hydrophilic) and the stationary phase is non-polar (hydrophobic).

The affinity between Non Polar-Non Polar and Polar-Polar links is higher than that between Polar-Non Polar connections.

Since most medications are hydrophilic, reverse phase chromatography is utilized more frequently.

• **II. BASED ON PRINCIPLE OF SEPERATION**

- **1. Absorption Chromatography 2. Ion-exchange chromatography**




Figure-2 *Absorption Chromatography*




Figure-3 *Ion-exchange chromatography*

• **3. Ion-pair chromatography**

Through a process known as "paired" chromatography, ions in solution can be neutralized and separated as an ion pair on a reversed-phase column.

- Ionic compounds with a hydrocarbon chain that provides a particular hydrophobicity to enable the retention of the ion pair on a reversed-phase column are commonly used as ion-pairing agents.

• **4. gel permeation chromatography**

- There is no compelling interaction between the stationary phase and the solute in this kind of chromatography. The gaseous or liquid phase flows through a porous gel that divides the molecules into smaller and larger groups based on size.

• **5. Affinity Chromatography**




Figure-4 *Affinity Chromatography*

• **Chiral chromatography**

- Stereoisomer separation is a part of it. Enantiomers are just mirror images in three dimensions; they differ neither chemically nor physically. They cannot be separated using other separation techniques like conventional chromatography. Either the stationary phase or the mobile phase must be rendered chiral in order for chiral separations to occur, resulting in different affinities between the analytes.

• **III. BASED ON ELUTION TECHNIQUE**

- ¹ **Isocratic elution:** • A solvent-only or solvent-mixture-based separation using a single, consistent solvent.

- ² **Gradient elution:** In this case, two or more solvent systems with noticeably different polarities are used. Following the start of elution, the solvent ratio is adjusted according to a preset protocol, sometimes step-by-step and other times constantly. Gradient elution significantly increases separation efficiency.

³ **IV. BASED ON SCALE OF OPERATION**

1. Analytical HPLC:

No recovery of the individual components of substance.

2. Preparative HPLC:

Individual components of substance can be recovered by preparative HPLC.

CONTENTS-ANALYTICAL METHOD DEVELOPMENT

For the analysis of novel products, new methods are being developed when there are no official methods available. In order to examine current pharmaceutical or non-pharmacopoeial products, innovative techniques are created to cut costs while improving precision and durability. Trial runs are used to optimize and validate these procedures. With all available benefits and drawbacks, alternative approaches are suggested and implemented to replace the current strategy in the comparative laboratory data.

1. Purpose of analytical method development :

The identification, characterization, and determination of pharmaceuticals in mixtures, such as dosage forms and biological fluids, are revealed by drug analysis. The primary goal of analytical methods in the manufacturing process and drug development is to provide information about potency (which can be directly related to the need for a known dose), impurity (related to the drug's safety profile), bioavailability (which includes important drug characteristics like crystal form, drug uniformity, and drug release), stability (which indicates the products of degradation), and the impact of manufacturing parameters to guarantee consistent drug product production. The goal of quality control is to evaluate and identify a true and correct product through a set of procedures meant to prevent and eliminate mistakes at various production stages. A product's release or disposal decision is based on one or more types of control actions. One of the most important topics is to provide an analytical and straightforward process for a variety of complex formulations. The need for new analytical techniques in the pharmaceutical industry has quickly increased due to the industries' rapid growth and ongoing drug production across the globe. As a result, developing analytical methods has become the primary analytical activity in a quality control laboratory. The following are the causes behind the creation of novel drug analysis techniques:

.when a medicine or drug combination is not listed as official in the pharmacopoeias.

a) When patent rules prevent the existing medicine from having a decorous analytical method listed in the literature.

b) When the interference brought on by the formulation excipients prevents the development of analytical techniques for the drug's formulation.

c) It is discovered that analytical techniques for measuring the analyte in bodily fluids are not readily available.

d) Expensive solvents and reagents might be required for the current analytical techniques. Moreover, laborious extraction and separation processes might be required.

2. Steps for the development of the method:

The development process is followed with the appropriate paperwork. Any information relevant to these investigations needs to be kept in a lab notebook or an electronic database.

3. Analyte standard characterization:

a) All relevant data on the structure and physicochemical characteristics of the analyte, such as optical isomerism and solubility, are gathered.

b) The analyte standard ($\approx 100\%$ purity) is acquired. It is necessary to set up the freezer, desiccators, and refrigerator for ideal storage.

c) When more than one component needs to be studied, the sample matrix appropriately notes the number of components, presents the data, and estimates the accessibility of standards.

d) When paired with sample stability, techniques such as spectroscopy, HPLC, GC, MS, etc., are taken into consideration.

4. Method requirements:

In order to design the analytical figures of merit, such as linearity, selectivity, range, accuracy, precision, detection limits, etc., the needs of the analytical method must be specified.

5. Literature search and prior methodology

It is very convenient to search Chemical Abstracts Service's automated computerized literature. All information related to the drug's literature is reviewed for physico-chemical properties, synthesis, solubility, and appropriate analytical methods with reference to pertinent books, journals, USP/NF, AOAC, and ASTM publications.

6. Choosing a method

a) The technique has evolved as a result of the procedures being modified as needed, using the material from the literature as appropriate. Sometimes it's necessary to acquire additional equipment in order to create, alter, duplicate, and validate current processes for analytes and samples.

b) In the event that the analyte to be investigated cannot be analyzed using any previously approved methods.

7. Instrumental setup and initial studies

By putting up the proper instruments, installation, operation, and performance qualification of the equipment are confirmed with reference to the laboratory standard operating procedures.

8. Optimization

Prior to applying a trial-and-error method, a set of conditions are isolated and one parameter is altered at a time during optimization. The aforementioned task must be completed using a rigorous, systematic strategy, carefully following each step, and documenting any dead ends.

9. Documentation of analytical figures of merit

Documentation is also provided for the actual determined analytical figures of merit, such as linearity, quantitation and detection limits, time spent for analysis, cost, sample preparation, etc.

10. Evaluation of development method with real samples

The drug's peak interest should be completely and unambiguously identified using the sample solution, independent of any other matrix elements.

11. Estimation of percent recovery of real samples and demonstration of quantitative sample analysis

An estimate is made of the percentage of spiked, real standard drug recovered into a sample matrix devoid of analytes. It is necessary to demonstrate optimization for recovery repeatability (average \pm standard deviation) across samples. Thus far, achieving a perfect recovery is not essential because the outcomes can be consistently identified with a high level of confidence.

Steps involve in method development are:

1. Recognize the drug molecule's physical characteristics.
2. Configure the HPLC settings.
3. Creating a sample solution in order to construct a method.
4. Optimizing the method.
5. Method validation

1. Understand the physicochemical properties of drug molecule

When developing a method, a medicinal molecule's physicochemical characteristics are crucial. The physical characteristics of the drug molecule, such as its pH, polarity, solubility, and pKa, must be studied in order to build a method. One of a compound's physical characteristics is polarity. It aids in the determination of the mobile phase's solvent and composition by the analyst. Two atoms share the same number of electrons in a nonpolar covalent link. When one atom is more attracted to the electrons than the other is a polar covalent bond.

The polarity of molecules provides an explanation for their solubility. Solvents that are polar, like water, and nonpolar, like benzene, do not combine. Like dissolves like, or that is, substances with comparable polarities are soluble in one another. The solubility of the analyte determines the choice of diluents. The analyte needs to dissolve in the diluents and not interact with any of the ingredients in the diluents. An essential factor in the development of HPLC methods is pH and pKa. The definition of pH is the negative of the hydrogen ion concentration's logarithm to base 10.

pH is equal to $-\log_{10}[\text{H}_3\text{O}^+]$.

Generally speaking, a substance's pH value determines how basic or acidic it is. Sharp, symmetrical peaks are frequently observed in HPLC when ionizable analytes are selected at the appropriate pH. To obtain low detection limits in quantitative analysis, sharp, symmetrical peaks are required.

2. Set up HPLC conditions:

A partially neutralized acid that is resistant to pH variations is called a buffer. Typically, salts like sodium lactate or citrate are employed to somewhat neutralize acids. The buffer's buffering capacity is its resistance to pH variations.

- (i) Buffering capacity rises with the buffer salt/acid solution's molar concentration, or molarity.
- (ii) The buffering capacity increases with the buffered pH's proximity to the pKa.
- (iii) The amount of sodium hydroxide needed to raise pH by 1.0 is the buffering capacity.

When developing the reversed-phase chromatography (RPC) method for ionic analytes, it is crucial to take into account factors such as the effect of pH on analyte retention, the kind and concentration of buffer to employ, its solubility in the organic modifier,

and its effect on detection. In reverse-phase separation of polar and ionizable chemicals, an inappropriate selection of buffer with respect to buffering species, ionic strength, and pH can lead to inadequate or non-reproducible retention and tailing^{8, 9}.

Buffer selection:

The ideal pH usually determines which buffer to use. Reversed phase on silica-based packing often occurs in a pH range of 2 to 8. Since buffers regulate pH best at its pKa, it is critical that the buffer's pKa be relatively near to the intended pH. Selecting a buffer with a pKa value less than two units of the intended mobile phase Ph is a general rule.

General considerations during buffer selection:

1. Compared to acetonitrile or THF/water, phosphate is more soluble in methanol/water.
2. There are hygroscopic salt buffers. Changes in chromatography (such as greater tailing of basic chemicals and potentially alterations in selectivity) may result from this.
3. In organic/water mobile phases, ammonium salts are often more soluble.
 4. TFA is volatile, can break down over time, and absorbs at low UV wavelengths.
6. *In buffered mobile phases with little to no organic modifier, microbial growth can happen rapidly. This growth can impair chromatographic performance as it accumulates on column inlets.*
7. *Phosphate buffer increases the dissolution of silica and significantly reduces the lifetime of silica-based HPLC columns at pH values higher than 7. Organic buffers should ideally be utilized at pH values higher than 7.*
8. *Ammonium bicarbonate buffers typically have a short half-life of 24 to 48 hours and are sensitive to pH variations. The emission of carbon dioxide causes this mobile phase's pH to gravitate toward becoming more basic.*
9. *After buffers are made, a 0.2- μ m filter needs to be used to filter them.*
10. *Degassing is necessary for mobile phases.*

Buffer selection

For tiny compounds, a buffer concentration of 10–50 mM is usually sufficient. In general, a buffer should be employed with no more than 50% organic material. This will vary based on the particular buffer and its concentration. For reversed-phase HPLC, phosphoric acid and its sodium or potassium salts are the most widely used buffer systems. When evaluating organophosphate compounds, sulfonate buffers can be used in place of phosphate buffers^{10, 11}.

Selection of detector

The detector is a crucial component of the HPLC. The choice of detector is influenced by the analytes' chemical makeup, possible interference, needed detection limit, detector availability, and/or detector cost. A flexible dual-wavelength absorbance detector for HPLC is the UV-visible detector. This detector provides the high sensitivity needed for regular UV-based applications, such as quantitative analysis and low-level impurity identification. Advanced optical detection for Waters analytical HPLC, preparative HPLC, or LC/MS system solutions is provided by the Photodiode Array (PDA) Detector. High chromatographic and spectral sensitivities are achieved by the advancements in optics and integrated software. The Refractive Index (RI) Detector is the best option for analyzing components with little to no UV absorption because of its excellent sensitivity, stability, and repeatability.

For quantifying tiny amounts of target substances, the Multi-Wavelength Fluorescence Detector provides high sensitivity and selectivity fluorescence detection¹².

Mobile phase Mobile Phase Reservoirs

- Inert container with inert lines leading to the pump are required.
- Reservoir filters (2-10 mm) at reservoir end of solvent delivery lines
- Degassed solvent
- Vacuum filtration
- Sparge with inert gas (N₂ or He)
- Ultrasonic under vacuum

Isocratic elution:

A separation using a single solvent or solvent mixture of constant composition.

Gradient elution:

Here, two or more solvent systems with markedly different polarities are used. After the elution process begins, the solvent ratio is set to change, sometimes continuously and sometimes in phases. Gradient elution improves separation efficiency significantly. The mobile phase affects resolution, selectivity, and efficiency. In reverse phase chromatography, the mobile phase is made up of an aqueous buffer and an organic solvent that is water miscible but not UV active. The effects of the organic and aqueous phases, as well as the amounts in which they are mixed, will have an impact on the drug molecule's analysis. The selection of the mobile-phase and gradient settings is determined by the analyte's ionogenic nature and the hydrophobicity of the analytes in the combination. The aqueous buffer serves multiple purposes. At low pH, the mobile phase protonates free silanols on the column, lowering peak tailing. At sufficiently low pH, basic analytes are protonated; when ionized, the analyte elutes faster but with a better

peak shape. Acidic analytes in buffers with a suitably low pH will remain uncharged, improving retention. At higher pH, neutral basic molecules are more likely to be maintained, whereas ionized acidic ones elute earlier. Peak splitting may occur if a compound's pKa is similar to that of the buffer and the analyte elutes as both charged and uncharged species. The retention of non-ionizable sample components is not significantly affected by a buffer's pH.

3.Preparation of sample solutions for method development

The drug substance being tested should be stable in solution (diluent). During the initial method development phase, solutions in amber flasks should be prepared until it is verified that the active component is stable at room temperature and does not degrade under standard laboratory settings. Filter the sample solution to remove particles. A 0.22 or 0.45 µm pore-size filter is recommended. Filtration is a preventative maintenance tool for HPLC analysis.

Sample preparation is a vital step in method development that the analyst should investigate. Syringe filters' efficacy is mostly influenced by its ability to remove contaminants/insoluble components while not introducing undesired artifacts (i.e., extractables) into the filtrate. If any further peaks are detected in the filtered samples, the diluent must be filtered to identify whether a leachable component is originating from the syringe filter housing/filter.

4. Method optimization

The experimental settings should be tuned to achieve the necessary separations and sensitivity after obtaining appropriate separations. Stability indicating test experimental circumstances will be obtained by conducting a systematic analysis of parameters such as pH (if ionic), mobile phase components and ratio, gradient, flow rate, sample quantities, injection volume, and diluent solvent type.

Validation of method

Validation of an analytical procedure is the process of determining, through laboratory research, if the procedure's performance characteristics fulfill the requirements for its intended usage. The methods validation process for analytical procedures begins with the applicant's planned and systematic collection of validation data to support the analytical procedures²¹. All analytical procedures intended for the analysis of clinical samples must be verified. The validation of analytical procedures follows ICH guidelines.

Components of method validation

The following are typical analytical performance characteristics that can be examined during technique validation:

1. System suitability.
2. Accuracy
3. Precision.
4. Repeatability.
5. Intermediate precision.
6. Linearity.
7. Limits of detection
8. Quantity limit.
9. Specificity
10. Range.
11. Robustness
12. Evaluating system appropriateness.
13. Studies on forced degradation.
14. Investigations into solution stability.

4.1. System Suitability:

System suitability assessment was originally considered by the pharmaceutical industry to determine whether a chromatographic system is routinely used in pharmaceutical laboratories where the quality of results is most important and suitable for a specific analysis.

The system suitability test (SST) report comprises the following parameters:

1. Efficiency, often known as the number of theoretical plates.
2. Capacity factor (K).
3. Separation or relative retention (α).
4. Resolution (RS).
5. Tail factor (T).
6. Relative standard deviation (RSD).

1. Number of theoretical plates/Efficiency (N)

Efficiency in a specific column is defined as the degree of peak dispersion, and it must have column characteristics. The efficiency is expressed as the number of theoretical plates. The formula for calculating N is illustrated below:




Figure 5 (Half Height Method).

N equals efficiency divided by the number of theoretical plates.

V_e = The analyte's retention time.

h is the height of the peak.

$w_{1/2}$ is a Gaussian function of the peak width at half-height.

Sigma/tangential method (USP method) : N is determined using the sigma/tangential approach, as shown in Figure 1.2, taking note of the formula for calculating N .




Figure 6. Sigma/tangential method relating to determination of N .

N = Number of theoretical plates.

V_e = elution volume, retention time or retention distance (mL, sec, or cm). h = peak height. w_b = width of the peak at the base line (mL, sec, or cm).

The plate number is determined by the length of each column. The theoretical plate number is a measure of column efficiency. According to plate theory, the analyte will be in immediate equilibrium with the stationary phase, and the column must be divided into a number of hypothetical plates, each of which has a defined height and where the analyte spends a finite amount of time. The height equivalent to theoretical plate (HETP) is given by the following formula:

$$\text{HETP} = L/N,$$

Where, (1) L = length of column. N = plate number

Capacity ratio or Capacity factor (k)

$$K' = t_R - t_M / t_M$$

The aforementioned capacity factor, also known as a retention factor, has no dimension and is independent of the flow rate of the mobile phase as well as column dimensions. It is a measure of the extent of retention linked to an analyte relative to an unretained peak. Where t_R represents the retention time of the sample peak and t_M represents the retention period of an unretained peak. $k' = 0$ indicates that no compound remains in the column. Generally, k' is greater than two.

Relative retention or separation factor (α) =

$t_2 - t_1 / t_1 - t_a$ represents relative retention. t_2 = Retention time determined from the site of injection.

t_a = Unretained peak time (t_R is the retention time of an inert component that the column did not retain).

t_1 is the retention time from the site of injection of the reference peak defined. (If no reference peak is detected, the value will be 0).

Resolution (Rs) :

Resolution is the column's capacity to separate two pharmaceuticals in two individual peaks or chromatographic zones, and it can be enhanced by increasing column length, decreasing particle size, increasing temperature, or changing the eluent or stationary phase. It can be expressed as the ratio of the separation of the apex of two peaks to their tangential width average.

$$R_s = (t_{R_2} - t_{R_1}) / 0.5 (t_{w_1} + t_{w_2})$$

Resolution is computed using the formula provided below.




Figure 7. Determination of resolution between two peaks. t_{R1}

t_{R1} and t_{R2} are the retention times for the two peaks of components. t_{w1} and t_{w2} = At the baseline lies between tangents drawn to the sides of the peaks. (Tangents are drawn at 0.6 times the peak height). If the peaks are correctly symmetric, provided the valley between the two peaks should touch the baseline R_s is 1.5. Generally good value of resolution is $R_s \geq 2$ should be adequate and preferred normally.

Resolution factor (R)

The number of theoretical plates (N) or capacity factor, selectivity, and efficiency all influence resolution. The proper capacity factor, ideally between 2 and 10, is needed to separate any two peaks, but you also need acceptable selectivity, ideally 1.2, and enough efficiency, or a sufficient number of theoretical plates (more than 2000 theoretical plates). $A \geq 1.5$ resolution is required. Baseline resolution is defined in 1.5. $R = k' / 1 + k'(\alpha - 1/\alpha) \sqrt{N/4}$

Tailing factor or Asymmetry factor

Under ideal circumstances, the chromatographic peak is said to have a Gaussian form. In actuality, though, there is always a divergence from the normal distribution, pointing to a process of non-uniform distribution and migration. Because of this, regulatory bodies such as USP and EP have suggested this as a system suitability measure. In most circumstances, the asymmetry factor and tailing factor are approximately equal, rarely correct, and equally distributed. Generally, values should fall between 1.0 and 1.5; numbers higher than 2 are not acceptable. The following formula is used to calculate the peak asymmetry. As is equivalent to B/A

(6)

.

Where: A_s = peak asymmetry factor.

B is the length of time between the trailing edge and the point at peak midpoint. (calculated as 10% of the maximum height). A is the length of time between the peak's leading edge and the middle. (calculated as 10% of the maximum height). Peaks should ideally have a Gaussian form or be perfectly symmetrical. Figure 1.5 displays the determination of the asymmetric factor and tailing.




Figure 8. Determination of tailing and asymmetric factor. Acceptance criteria (limits) of system suitability parameters are shown in the following Table 1.1.

Sr. No	Parameter name	Acceptance criteria
1	Number of theoretical plates or Efficiency (N)	> 2000
2	Capacity factor (K)	< 1
3	Separation or Relative retention (α)	> 1
4	Resolution (Rs)	> 1.5
5	Tailing factor or Asymmetry(T)	< 2
6	Relative Standard Deviation (RSD)	< 2

Fig. 1. SPECIFICITY

The capacity to evaluate the analyte without a doubt in the presence of potentially present components is known as specificity. Usually, these could consist of matrix, degradants, contaminants, etc.

Other supporting analytical procedure(s) may make up for a particular analytical procedure's lack of specificity. The following conclusions flow from this definition:

Identifying: To confirm an analyte's identity.

Purity tests: Verify that every analytical process carried out, such as the related substances test, heavy metals, residual solvents content, etc., enables an accurate assessment of the impurity level of an analyte.

Assay (content or potency): To yield a precise result that permits a precise declaration of the analyte's content or potency in a sample

3. ACCURACY

The degree of agreement between the value found and the value acknowledged as either a conventional true value or an acceptable reference value is what determines an analytical procedure's accuracy.

4. PRECISION

The precision of an analytical technique expresses the closeness of agreement (degree of scatter) between a set of measurements acquired from multiple sampling of the same homogenous sample under the defined conditions. Three levels of accuracy can be distinguished: reproducibility, moderate precision, and repeatability. Investigations into precision should be conducted with true, uniform samples. On the other hand, artificially generated samples or a sample solution may be used for investigation if a homogeneous sample cannot be obtained. A set of measures' variance, standard deviation, or coefficient of variation are typically used to express how precise an analytical process is.

4.1. Repeatability

Repeatability is the ability to convey precision over a brief period of time under the same operational conditions. Another name for repeatability is intra-assay precision.

4.2. Intermediate precision

Variations within laboratories, such as various days, analysts, equipment, etc., are expressed as intermediate precision.

4.3. Reproducibility

The precision between laboratories is expressed by reproducibility (collaborative investigations, usually used to standardization of methodology).

5. DETECTION LIMIT

The lowest concentration of analyte in a sample that can be identified but may not always be quantified as an exact number is known as the detection limit of a particular analytical technique.

6. QUANTITATION LIMIT

The lowest concentration of analyte in a sample that can be quantitatively identified with appropriate precision and accuracy is known as the quantitation limit of a particular analytical process. When determining impurities and/or degradation products, the quantitation limit is a parameter of quantitative assays for low concentrations of chemicals in sample matrices.

7. LINEARITY

The capacity of an analytical method to produce test findings that are exactly proportionate to the concentration (amount) of analyte in the sample, within a specified range, is known as linearity.

8. RANGE

The range of an analytical technique is the range of the analyte concentration (amounts) in the sample, including these concentrations, for which the analytical procedure has been shown to have an appropriate degree of linearity, accuracy, and precision.

9. ROBUSTNESS

An analytical procedure's resilience to tiny, intentional changes in method parameters is measured by its robustness, which also indicates how reliable it is under typical operating conditions.

Forced Degradation Studies

In order to evaluate an analytical method's capacity to measure an active ingredient and its degradation products, without interference, forced degradation or stress studies are conducted to purposefully degrade the sample. Potential degradation products are generated during method validation, when drug substances are exposed to heat, light, acidity, base, and oxidizing agents, resulting in approximately 10% to 30% degradation of the active substance. The studies can also offer insights into potential degradation pathways and degradation products that may form during storage.

These research could potentially be useful in improving drug products through formulation development, manufacturing, and packaging. The development and validation of stability-indicating methodology, the identification of drug substance and drug product degradation pathways, and the differentiation of degradation products in formulations related to drug substances versus those related to non-drug substances (e.g., excipients) are among the reasons why forced degradation studies are conducted.

Solution Stability Studies

stability of standards and samples is established during validation in typical circumstances, under typical storage conditions, and occasionally inside the instrument to ascertain whether particular storage conditions—such as refrigeration or light protection. In order to ascertain whether certain storage conditions, such as refrigeration or light protection, are required, the stability of standards and samples is established during validation under normal settings, normal storage conditions, and occasionally in the instrument^{27, 28}

.Methods of HPLC Derivatization A Why would you derivatize?

Boost detector responsiveness and analyte resolution.

Enhance the form of the analyte peak.

Boost the sensitivity of the analyte.

Determine which analyte is which.

Boost analyte stability while conducting analysis.

Alter the physicochemical characteristics of analytes.

Conclusion

The parameters for method validation are defined and explained in detail. In the pharmaceutical business, validation in accordance with ICH principles is a crucial step that's used to make sure quality is ingrained in the operations that support medication research and manufacture.

The overall methodology for developing HPLC methods and validating optimized methods is covered in this article. Before developing the HPLC process, it is crucial to understand the pKa, pH, and solubility of the main component. Changes in temperature, gradient slope, flow rate, and mobile-phase modifier type and concentration can all be made for the final optimization.

References:

1. A Review on Step-by-Step Analytical Method Validation, Panchumarthy Ravisankar* IIOSR, Journal Of Pharmacy www.iosrphr.org Volume 5, Issue 10 (October 2015), PP. 0719.
2. Development and validation of HPLC method - a review, Vibha Gupta et al, International Research Journal of Pharmaceutical and Applied Sciences, 2012; 2(4):17-25.
3. A Review: HPLC Method Development and Validation, Santosh Kumar Bhardwaj *et al.
4. International Journal of Analytical and Bioanalytical Chemistry, accepted 20 November 2015.
5. Method Development: a Guide to Basics Quantitative & Qualitative HPLC, LC, GC chromatography.
6. Lalit V Sonawane* Bioanalytical Method Validation and Its Pharmaceutical Application- A Review Pharmaceutica Analytica Acta 2014, 5:3 Center for Drug Evaluation and Research (CDER) Reviewer Guidance
7. ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology.
8. Validation of Chromatographic Methods. Development and validation of a simple reverse phase HPLC-UV method for determination of oleuropein in olive leaves, Fuad AlRimawi* Elsevier, science direct journal of food and drug analysis 22(2014) 285 -289.
9. "Principles of Instrumental Analysis", 5th edition, Harcourt Publishes Int Company, Skoog, Holler and Nieman, Chapter 28, p.726-766.
10. "HPLC Columns" Theory, Technology and Practice. Uwe D. Neue, Wiley-VC
11. Handbook of HPLC, Vol.78, by Elena Katz et al. Marcel Dekker Inc.
12. "Instrumental Methods of Chemical Analysis", 5th Edition, Galen W. Ewing, McGraw Hill Book Company 1988.
13. "HPLC in Pharmaceutical Industry", Fong and Long, Marcel Dekker Series
14. "Instrumental Method of Chemical Analysis" by Chatwal Anand, Himalaya Publishing House, p.no.615-623.

15. "Practical Pharmaceutical Chemistry", 4th edition, Part 2, by Beckett and Stenlake, CBS Publishers and Distributors, P.No.157-174.
16. *Govt. of India, Ministry of Health and Family Welfare*. Vol. 2. Delhi: Publication by Controller of Publication; 2007. Indian Pharmacopoeia; pp. 484–554.
17. *British Pharmacopoeia*. (International ed.) 1993;Vol. 1:429, 483. Published on the Recommendation of the Medicines Commissions Pursuant to Medicines Act 1968, 1993.
18. United States Pharmacopoeia 29 NF 24, Published on the Recommendation of the Medicines Commissions Pursuant to Medicines, page no. 587
19. Skoog, West, Holler, Crouch, "Fundamentals of analytical chemistry", eighth edition, 2009 (Indian edition), cengage learning India pvt ltd , New delhi, pageno. 271-280.
20. A.V Kasture, K.R Mahadik, S.G Wadodkar, H.N. More, "A textbook of pharmaceutical analysis, Instrumental methods", Nirali Prakashan, vol.2, 9th edition, page no. 5-7, 28-30

